 Alterations in the oral microbiome in HIV infection: causes, effects and potential interventions

Shuang Li¹, Bin Su¹, Qiu-Shui He², Hao Wu¹, Tong Zhang¹

¹Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China; ²Institute of Biomedicine, Research Center for Infections and Immunity, University of Turku, Turku 20520, Finland.

Abstract
A massive depletion of CD4⁺ T lymphocytes has been described in early and acute human immunodeficiency virus (HIV) infection, leading to an imbalance between the human microbiome and immune responses. In recent years, a growing interest in the alterations in gut microbiota in HIV infection has led to many studies; however, only few studies have been conducted to explore the importance of oral microbiome in HIV-infected individuals. Evidence has indicated the dysbiosis of oral microbiota in people living with HIV (PLWH). Potential mechanisms might be related to the immunodeficiency in the oral cavity of HIV-infected individuals, including changes in secretory components such as reduced levels of enzymes and proteins in saliva and altered cellular components involved in the reduction and dysfunction of innate and adaptive immune cells. As a result, disrupted oral immunity in HIV-infected individuals leads to an imbalance between the oral microbiome and local immune responses, which may contribute to the development of HIV-related diseases and HIV-associated non-acquired immunodeficiency syndrome comorbidities. Although the introduction of antiretroviral therapy (ART) has led to a significant decrease in occurrence of the opportunistic infections in HIV-infected individuals, the dysbiosis in oral microbiome persists. Furthermore, several studies with the aim to investigate the ability of probiotics to regulate the dysbiosis of oral microbiota in HIV-infected individuals are ongoing. However, the effects of ART and probiotics on oral microbiome in HIV-infected individuals remain unclear. In this article, we review the composition of the oral microbiome in healthy and HIV-infected individuals and the possible effect of oral microbiome on HIV-associated oral diseases. We also discuss how ART and probiotics influence the oral microbiome in HIV infection. We believe that a deeper understanding of composition and function of the oral microbiome is critical for the development of effective preventive and therapeutic strategies for HIV infection.

Keywords: HIV; Oral microbiome; Antiretroviral therapy; Probiotics; Intervention

Introduction
Human immunodeficiency virus (HIV) infection is characterized by severe deficiency of the host immune system through the massive depletion of CD4⁺ T cells. The World Health Organization reported that, in the end of 2019, approximately, 38 million people were living with HIV worldwide, with around 67% of them receiving antiretroviral therapy (ART). Despite effective ART, several oral diseases, such as oropharyngeal candidiasis (OPC)[1,2] and periodontitis,[3,4] are frequently reported in all stages of HIV infection. In addition, as the life expectancy in people living with HIV (PLWH) increases, the risk of HIV-associated non-acquired immune deficiency syndrome (AIDS) comorbidities such as cardiovascular disease, neurocognitive disorders, cancer, and liver and kidney disease is increasingly reported.[5-7] Ryder et al[8] also found that older HIV-infected individuals who have received ART may present with a higher incidence of age-related oral diseases.

In recent years, several studies have shown that the composition of the gut microbiome in PLWH differs from that of HIV-uninfected individuals, including an increase in the abundance of Prevotella and a decrease in the abundance of Bacteroides.[9-12] Alterations in the gut microbiome may promote HIV-associated inflammation and immune activation.[11,13] Similarly, Annavajhala et al[14] suggested that oral microbiome diversity may also play a critical role in systemic inflammation in HIV-infected individuals. Studies have found that CD4⁺ T lymphocytes in gut-associated lymphoid tissue are greatly reduced in the early stage of HIV infection,[16] resulting in the loss of T helper (Th) 17 cell subsets.[17] It is believed that these interleukin-17- and interleukin-22-
microbiome and includes different microbes e.g., bacteria, The human oral microbiome in HIV-infected individuals. Studies have indicated that Th17 cells are essential for the control of fungal colonization. The oral mucosa contains 775 microbial species e.g., bacteria, fungi, viruses, mycoplasma, and protozoa. Bacteria are the predominant group of the oral microbiome, of which approximately 700 bacterial species have been identified. The oral microbiome plays a critical role in human metabolism, physiology, and immunity, including inhibiting pathogenic microorganism colonization, maintaining the acid-base balance, regulating local oral immunity, and participating in salivary nitrate metabolism. The human oral microbiome

The human oral microbiome is an important part of the human microbiome and includes different microbes e.g., bacteria, fungi, viruses, mycoplasma, and protozoa. Bacteria are the predominant group of the oral microbiome, of which approximately 700 bacterial species have been identified. The oral microbiome plays a critical role in human metabolism, physiology, and immunity, including inhibiting pathogenic microorganism colonization, maintaining the acid-base balance, regulating local oral immunity, and participating in salivary nitrate metabolism. The human oral microbiome Database (http://www.homd.org/) contains records for a total of 775 microbial species. Among them, approximately 57% have been cultivated and named, 13% can be cultivated but not named, and 30% are uncultivated. Many of them have unique living conditions, such as specific temperature, pH, nutrition, and interaction with other species. The inability to fully replicate the ecological conditions in the oral cavity may be the reason why some oral microbiota cannot be cultivated artificially. The human oral bacterial microbiome consists primarily of six phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes, and Fusobacteria. Bik et al. analyzed the bacterial diversity in the oral cavity of ten healthy individuals and found that the most abundant genus was Streptococcus, followed by Haemophilus, Neisseria, Prevotella, Veillonella, and Rothia, similar to other reports on the oral microbiome. In addition to bacterial communities, different fungi are also widely colonized in the human oral cavity. It is known that in elderly and immunocompromised individuals, oral commensal fungi can also serve as opportunistic pathogens. Ghannoum et al. used internal transcribed spacer (ITS) sequencing to characterize the oral mycobiome in healthy individuals. This study demonstrated that the oral mycobiome comprises 74 culturable and 11 nonculturable fungal genera. In the samples from 20 healthy individuals, the most common genera were Candida (75%), followed by Cladosporium (65%), Aureobasidium and Saccharomyces (50% for both), Aspergillus (35%), Fusarium (30%), and Cryptococcus (20%).

The alterations in the oral microbiome in HIV infection

The homeostasis of oral microbiota can be affected by multiple factors, including diet, smoking, and drugs. Moreover, changes in secretory components in saliva, innate and adaptive immune responses, and the physiological structure and function of the oral mucosa can also cause the dysbiosis of the oral microbiome. Indeed, several studies have demonstrated a significant difference in the alterations of the oral microbiome between PLWH and HIV-uninfected healthy controls. However, the potential mechanisms of oral microbiota changes in HIV infection remain unclear.

Alterations in salivary composition and function in HIV infection might play a key role in the dysbiosis of the oral microbiome. Saliva contains a variety of secretory components that are essential for maintaining oral homeostasis. Studies have shown that secretory components, including immunoglobulin A (IgA), lysozyme, and host defense peptides, such as antimicrobial peptides, defensins, and histones, play an important role in microbial control and oral mucosal immunity. A recent study indicated the composition and function of saliva change in HIV infection. The impairment of local immunity in HIV infection, including decreased salivary IgA, defensins, and cytokines, might convert commensal microorganisms to microorganisms with increased pathogenicity and lead to the dysbiosis of oral microbiota, which could increase the risk of opportunistic infections. Arirachakaran et al. showed that HIV-infected individuals, regardless of whether they are receiving ART, have a higher frequency and load of opportunistic microorganisms than HIV-uninfected controls. Other studies also revealed that the diversity and bacterial load in salivary samples from HIV-infected individuals were significantly higher than those in HIV-uninfected samples. In addition, a negative correlation between oral lesions and CD4+ T-cell counts has
been reported. Therefore, the disruption of oral mucosal immunity in HIV infection might destroy the colonization of commensal bacteria in the oral cavity and lead to an increase in oral microbial diversity, resulting in an increased risk of HIV-associated oral diseases. However, different studies have also shown differing results. They found that the oral bacterial diversity in PLWH was significantly decreased when compared with that in HIV-uninfected individuals. A possible explanation might be the increased proportion of opportunistic pathogens caused by immunodeficiency in HIV infection. Furthermore, a variety of salivary proteins, such as lysozyme, defensin, lactoferrin, secretory leukocyte protease inhibitor, and salivary agglutinin, have been confirmed to inhibit HIV infectivity in vitro, which also shows the importance of changes in salivary components in the pathogenesis of HIV infection.

In addition to the secretory components, cellular innate immune components in the oral cavity, e.g., macrophages, natural killer cells, polymorphonuclear leukocytes, and dendritic cells, also have the capacity to protect the oral mucosa from the colonization of pathogenic microorganisms. These innate immune cells can recognize pathogens such as bacteria, viruses, and fungi through pattern recognition receptors (PRRs). PRRs mainly comprise several families, including Toll-like receptors, C-type lectin receptors, retinoic acid inducible gene-like receptors, and nucleotide-binding oligomerization domain-like receptors. The binding of these PRRs to the pathogen-associated molecular patterns presented on the surface of microorganisms will induce the production of cytokines, chemokines, and vasoactive molecules, which might play important roles in regulating the innate immune response to infection and promoting the induction of adaptive immune responses. Therefore, these innate immune cells are essential for the prevention of bacterial infections. However, innate immune responses in the oral cavity are impaired in HIV infection, which may lead to the dysbiosis of the oral microbiome and increase the occurrence of opportunistic infections.

In addition, immunodeficiency associated with HIV infection might lead to defects in the adaptive immune response, which could also promote oral microbiota dysbiosis. A number of studies have shown that the Th17 immune response is essential for the control of fungal infection and inflammation of the oral mucosa. Dutzan et al. found that Th17 cells could maintain oral barrier integrity and aid in fighting oral fungal infections. Furthermore, the critical role of Th17 cells in the fight against Candida infection has been described in a previous study. In addition, Th1 cells might mediate early gingival inflammatory lesions in response to bacterial plaques by producing cytokines such as interferon γ (IFN-γ). Th2 immune responses are also closely related to the progression of periodontal disease.

Although previous studies have demonstrated that oral microbiome composition might change in HIV infection, the results obtained from the different studies are not the same. A recent study compared saliva micro-

Figure 1: Proposed mechanisms of oral microbiome dysbiosis in HIV infection. In health, oral epithelial cells have the capability to maintain microbial colonization. However, disrupted oral immunity, including changes in secretory components in saliva (sIgA, lysozyme, and antimicrobial peptides), deficiency of innate immune responses (macrophages and dendritic cells), and adaptive immune response (CD4+ Th1), may cause oral microbiome dysbiosis in HIV infection. Such an imbalance between the oral microbiome and oral immune responses may also contribute to the development of HIV-related oral diseases (periodontal disease) and HIV-associated non-AIDS comorbidities. Periodontal disease is caused by the interplay between pathogenic bacteria and host defense, which can also lead to microbial translocation and an increased risk of systemic conditions. AIDS: Acquired Immune Deficiency Syndrome; HIV: Human immunodeficiency virus; IgA: Immunoglobulin A; IFN-γ: Interferon-γ; IL-4: Interleukin-4; Th: T helper.
Table 1: The oral microbiome in HIV infection.

| Study | Cohort | Samples | Design | Major findings |
|-------|--------|---------|--------|----------------|
| Li et al[46] | 10 HIV+ subjects prior to and after 6 months of ART | 10 HIV+ subjects and 10 HIV- controls | Cross-sectional and longitudinal | • Increased oral streptococci, lactobacilli, Streptococcus mutans, and Candida in HIV. |
|  |  |  |  | • Increased Fusobacterium, Campylobacter, Prevotella, Capnocytophaga, Selenomonas, Actinomyces, Granulicatella, and Atopobium and decreased Aggregatibacter after ART. |
| Beck et al[99] | 18 HIV+ naive | Oral wash | Cross-sectional | • Enrichment of a Streptococcus Operational taxonomic unit (OTU) and two Actinomyces OTUs in HIV+ naive subjects, an Atopobium OTU in HIV+ naive and ART subjects, and a Rothia OTU in ART. |
| Saxena et al[47] | 46 HIV+ subjects before and after ART and 69 HIV- controls | 8 HIV+ subjects and 8 HIV- subjects | Cross-sectional and longitudinal | • Different microbial compositions among HIV+ subjects before and after ART and HIV- controls. |
|  |  |  |  | • Differences in Streptococcaceae, Prevotellaceae, Porphyromonadaceae, and Neisseriaceae between HIV+ and HIV- subjects. |
| Arirachakaran et al[48] | 148 HIV+ ART for >5 years | Tongue, gingival crevices, and mucosal lesions | Cross-sectional | • Higher frequency and load of opportunistic microorganisms in the ART group and non-ART group than the HIV- controls. |
|  | 20 HIV+ untreated vertically transmitted ART HIV+ subjects | 53 HIV- controls |  | • Increased Candida spp. on the tongue in HIV+ subjects with CD4+ counts <500 cells/mm³. |
| Presti et al[41] | 35 HIV+ subjects prior to and after 6 months of ART | Saliva | Longitudinal | • Higher bacterial richness and diversity in HIV+ subjects with persistently low CD4 counts after 24 weeks of ART. |
|  |  |  |  | • Differences in several taxa, including Porphyromonas species discriminated between HIV+ subjects before and after 6 months of ART. |
| Starr et al[65] | 154 perinatally HIV-infected youth | Subgingival plaque | Cross-sectional | • Similar microbiomes in the two cohorts. |
|  | 100 perinatally HIV-exposed, uninfected youth |  |  | • Two Corynebacterium species were lower in perinatally HIV-infected youth. |
| Mukherjee et al[51] | 48 HIV-infected smokers | Oral wash | Cross-sectional | • Decreased Firmicutes and increased Proteobacteria in HIV-infected non-smokers compared to HIV-infected smokers and HIV-uninfected smokers. |
|  | 24 HIV-infected non-smokers | 24 HIV-uninfected smokers |  | • No difference in fungal phyla between the three cohorts. |

(continued)
| Study                        | Cohort                                                                 | Samples                      | Design                     | Major findings                                                                                   |
|-----------------------------|------------------------------------------------------------------------|------------------------------|----------------------------|-------------------------------------------------------------------------------------------------|
| Gonçalves et al\[63\]       | 27 HIV+ Brazilian children/teenagers 30 HIV− children/teenagers        | Whole saliva, biofilm from the dorsal surface of the tongue, and biofilm from supragingival and subgingival sites | Cross-sectional            | - Higher frequency of the phyla *Firmicutes* and genus *Streptococcus* in HIV-infected children/teenagers  
|                             |                                                                        |                              |                            | - More complexity in oral microbiome of HIV-infected children/teenagers                          |
| Jiménez-Hernández et al\[49\] | 12 viremic ART-untreated 18 immunological ART responders 9 immunological ART non-responders 14 HIV-uninfected controls | Saliva                       | Cross-sectional and longitudinal | - Higher abundance of potential pathogens as *Streptococcus agalactiae*, *Corynebacterium durum*, and OTUs assigned to species of *Prevotella*, *Leptotrichia*, *Tannerella*, and *Catonella* in HIV+ subjects  
|                             |                                                                        |                              |                            | - Increased *Actinobacteria*, *Rothia mucilaginosa*, *Mogibacterium* and decreased *Corynebacterium*, *Fusobacterium*, and *Prevotella meleaginosa* in viremic ART-untreated subjects after prebiotics |
| Coker et al\[95\]          | 94 HIV+ children 98 HIV exposed-uninfected children 94 HIV unexposed/uninfected children | Saliva                       | Cross-sectional            | - Depletion of eight bacterial taxa, including *Actinomyces* and *Neisseria subflava* and enrichment of *Corynebacterium diphtheriae* in HIV+ children when compared to HIV unexposed/uninfected children  
|                             |                                                                        |                              |                            | - Low CD4 levels persistently alter the oral microbiota.                                          |
| Griffen et al\[40\]        | 252 HIV+ ART 89 HIV−                                                  | Oral rinse                    | Cross-sectional            | - A complex set of clinical features that influenced oral bacterial community composition, including the presence of HIV under ART  
|                             |                                                                        |                              |                            | - Increased *Veillonella*, *Rothia*, and *Streptococcus* and decreased *Neisseria*                  |
| Yang et al\[39\]           | 75 HIV+ ART 93 HIV−                                                   | Saliva                       | Cross-sectional            | - Bacterial and fungal oral microbiome communities were associated with chronic systemic immune activation in HIV.  
|                             |                                                                        |                              |                            | - Increased *Streptococcus* and decreased *Neisseria* in HIV+ subjects  
|                             |                                                                        |                              |                            | - *Prevotella_7*, *Neisseria*, and *Haemophilus* negatively correlated with CD4$^+$ T cell count, while *Neisseria* positively correlated with viral load. |
| Annavajhala et al\[15\]    | 52 HIV+ ART                                                           | Saliva and plaque samples    | Cross-sectional and longitudinal | - No largely differences in three major genera, *Prevotella*, *Streptococcus*, and *Veillonella* between the HIV+ subjects and controls. |
| Li et al\[38\]             | 20 HIV+ subjects before and after 6 months ART 20 HIV− controls       | Saliva                       | Cross-sectional and longitudinal | - No largely differences in three major genera, *Prevotella*, *Streptococcus*, and *Veillonella* between the HIV+ subjects and controls. |
| Imahashi et al\[64\]       | 20 HIV+ Japanese with ART 13 HIV− controls                           | Saliva                       | Cross-sectional and longitudinal | - No largely differences in three major genera, *Prevotella*, *Streptococcus*, and *Veillonella* between the HIV+ subjects and controls. |
biome samples from HIV-infected individuals and HIV-uninfected controls. They found that the abundance of *Streptococcus* was increased in HIV-infected individuals, while the abundance of *Neisseria* was higher in healthy controls.[38] Another study showed similar results: the abundance of *Veillonella*, *Rothia*, and *Streptococcus* was significantly increased in the oral microbiome of PLWH, whereas the abundance of *Neisseria* was significantly decreased.[139] The oral microbiome in HIV-infected children and teenagers is also characterized by a higher frequency of the phyla *Firmicutes* and the genus *Streptococcus*.[63] However, other studies have shown that there are no large differences in the oral microbiome between HIV-treated patients and healthy controls.[64,65] In addition, alterations in the oral fungal community composition in PLWH have also been noted when compared with those in HIV-uninfected individuals.[66] A study compared the oral fungal composition of 12 HIV-infected individuals with that of 12 HIV-uninfected individuals.[67] The oral microbiome in HIV-infected children and teenagers is also characterized by a higher frequency of the phyla *Firmicutes* and the genus *Streptococcus*.[63] However, other studies have shown that there are no large differences in the oral microbiome between HIV-treated patients and healthy controls.[64,65] In addition, alterations in the oral fungal community composition in PLWH have also been noted when compared with those in HIV-uninfected individuals.[66] A study compared the oral fungal composition of 12 HIV-infected individuals with that of 12 HIV-uninfected individuals.[67] The study showed that *Candida*, *Epicoccum*, and *Alternaria* were the most common, presenting in 92%, 33%, and 25% of HIV-infected individuals, respectively. However, the most abundant fungi in HIV-uninfected controls were *Candida*, *Pichia*, and *Fusarium*, presenting in 58%, 33%, and 33%, respectively.[67] Fidel et al.[68] have also demonstrated the relative abundance of oral fungal communities in 149 HIV-positive and 88 HIV-negative subjects. This study suggested that 168 species can be identified in 12 dominant genera by sequencing of the ITS2 region of the rRNA gene repeat. However, they indicated that the diversity of the oral mycobiome is usually dominated by a small number of species, and HIV and ART might affect the oral mycobiome composition. In addition, many studies have shown increased *Candida* colonization in HIV infection.[11,15,69,70] These studies support that HIV infection can significantly change the host oral microbiota. However, the effects of an altered oral microbiome on HIV-associated diseases remain to be shown.

**Effects of the oral microbiome on HIV-associated oral diseases**

The oral microbiome is known to play an important role in host health and disease. On the one hand, the dysbiosis of the oral microbiome has been found in people with various oral diseases, such as dental caries, periodontal diseases, oral mucosal diseases, and oral cancer.[71] On the other hand, the dysbiosis of oral microbiota has also been observed in digestive system diseases (inflammatory bowel disease,[72-74] liver cirrhosis,[75] pancreatic cancer,[76,77]) nervous system diseases (Alzheimer disease,[78,79]), endocrine system diseases (diabetes,[80]), immune system diseases (rheumatoid arthritis,[81,82] HIV infection,[83]), cardiovascular diseases (atherosclerosis,[84]), adverse pregnancy outcomes,[84] and polycystic ovary syndrome.[85] The potential mechanisms may be that oral microbiota could enter the gastrointestinal tract and respiratory tract through eating and aspiration. Moreover, Han et al.[86] reported that oral microbial dysbiosis could promote adverse systemic conditions through bacteremia. Studies have also shown that periodontal disease caused by the interaction between pathogenic microorganisms and host defenses can lead to microbial translocation and an increased risk of inflammatory diseases, such as cardiovascular diseases.[87,88] Therefore, the systemic translocation of the oral microbiome might also contribute to systemic diseases.

The oral cavity is one of the most common sites for opportunistic infections in PLWH. Several oral diseases often occur in PLWH, including periodontal diseases, OPC, oral warts, oral hairy leukoplakia, and Kaposi sarcoma (KS), even in those receiving ART.[44] Globally
and throughout the decades, OPC has remained the most common oral manifestation in HIV infection, including among HIV-infected individuals receiving ART (26.2%).[89] OPC is caused by various Candida species, and Candida albicans is the most prevalent species isolated from PLWH.[70,90,91] The incidence of OPC in HIV infection is influenced by a multitude of factors, including immune status,[92] bacteriome-mycobiome interaction,[93] antifungal therapy, and ART.[94] Patil et al[91] showed that oral Candida colonization in HIV-infected patients increased, and it was significantly related to a lower CD4+ T-cell count. Coker et al[93] also demonstrated that low CD4+ T-cell levels in HIV-infected children might persistently alter oral microbiota. In addition, other studies found that the prevalence of dental caries and periodontal diseases in PLWH was increased, which may be related to changes in oral microbiota in HIV-infected patients.[3,96]

Compared with PLWH with mild periodontal disease, Abiotrophia, Rothia, and unclassified Pasteurellaceae were enriched in HIV-infected individuals with moderate and severe periodontal disease, and Treponema spp. were enriched in patients with severe periodontal disease.[4] Moreover, Marion et al. found that oral microbiota composition in HIV-infected individuals with oral KS was significantly different from that of HIV-infected individuals without oral KS. They found that at the genus level, the abundances of Aggregatibacter and Lautropia were decreased, whereas those of Corynebacterium and Shuttleworthia were increased in HIV-infected individuals with oral KS.[97] These studies indicated that distinct oral microbiota might affect the development of oral diseases in PLWH.

**Effects of potential interventions on the oral microbiome**

Although the use of ART can inhibit HIV replication, increase CD4+ T lymphocytes, and reduce the occurrence of oral lesions, it cannot completely restore the oral microbiome of PLWH from its dysbiosis to normal.[3,98] Studies observed that the oral microbiome compositions in HIV-infected individuals with ART became more similar to those in HIV-uninfected controls; however, a difference remained between the groups.[38,99] Annavajhala et al.[15] indicated that the use of specific ART regimens was associated with alterations in both gut and oral bacterial diversity. A study showed that Fusobacterium, Campylobacter, Prevotella, Capnocytophaga, Selenomonas, Actinomyces, Granulicatella, and Atopobium were increased in HIV-infected individuals after receiving ART, while Aggregatibacter was significantly decreased.[45] Another study collected samples from 35 HIV-infected subjects at baseline and after 24 weeks of ART to compare the differences in oral microbiota. The results showed that the dominant phyla in samples from patients with 24 weeks of ART remained similar to those observed at baseline, and the diversity was not significantly different between samples collected at baseline and those collected after 24 weeks of ART. However, PLWH with persistently low CD4+ T-cell counts had significantly increased bacterial richness and Shannon diversity, indicating that shifts in oral microbiota may play an important role in the recovery of CD4+ T-cell counts.[46] A recent study also found that Prevotella_7, Neisseria, and Haemophilus were negatively correlated with CD4+ T-cell count, whereas *Neisseria* was positively correlated with viral load.[37] Imahashi et al[64] also revealed the effects of long-term ART on gut and oral microbiota in PLWH. They suggested that ART, especially nucleoside reverse transcriptase inhibitor-based ART, has more suppressive effects on the composition and diversity of microbiota in the gut than that in the oral cavity.

Although OPC is still the most common oral opportunistic infection in PLWH, the introduction of ART can reduce its incidence in PLWH.[1] Interestingly, Maurya et al.[100] found that although ART can decrease the risk of OPC in HIV-infected individuals, it does not decrease the colonization of *Candida* in the oral cavity. ART may play a key role in maintaining homeostasis between host immunity and the oral microbiome. However, it can also reduce oral commensal microorganisms that are capable of inhibiting pathogen colonization. Therefore, the potential mechanisms of ART on oral microbiome colonization remain unclear, and the further studies are necessary.

In addition to ART, many studies have demonstrated that probiotics can be used as a new therapeutic approach to improve the quality of life in PLWH.[101] Probiotics play a beneficial role in human health by regulating the immune system and controlling pathogen colonization.[102] Studies have shown that probiotics are effective in preventing and treating many disorders, such as acute gastroenteritis,[103] inflammatory bowel diseases and irritable bowel syndrome,[104,105] Clostridium difficile-associated diarrhea,[106] allergies,[107] neonatal sepsis,[108] and respiratory tract infections.[109] Hu et al.[110] also reported that probiotics might exert their beneficial effects on coronavirus and have a positive effect on host immune functions during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In recent years, probiotics have also been used to prevent various oral diseases, such as dental caries,[111] gingivitis,[112] and periodontitis.[113] In addition, the administration of probiotics could have a beneficial effect on OPC.[114,115] De Barros et al.[116] found that *Lactobacillus* could reduce the filamentation of *C. albicans* in *in vitro* and *in vivo* models, presenting the suppressive effect of probiotics on fungal pathogens. Other studies also showed that intake of *Lactobacillus rhamnosus* by immunosuppressed mice might decrease the development of candidiasis.[117] An *in vitro* study also suggested that *Lactobacillus acidophilus* and *Lactobacillus plantarum* had antifungal effects against different oral *Candida* species isolated from HIV/AIDS patients.[118] In addition, recent studies also focused on the intervention of prebiotics and found nutritional stimulation of beneficial bacteria by prebiotics might play a crucial role in promoting oral health.[119,120] Jiménez-Hernández et al.[49] conducted a study on the impact of prebiotic intervention on the saliva microbiome of PLWH. A total of 32 HIV-infected subjects completed a 6-week prebiotic intervention, including viremic ART-un-treated patients, immunological ART responders, immunological ART non-responders, and HIV-uninfected controls. The diversity and richness of the saliva microbiome were decreased in the four groups after prebiotic intervention. In viremic ART-un-treated individuals, the Actinobacteria Rothia mucilaginosa was increased, whereas some potential pathogens, such as
Corynebacterium, Fusobacterium, or Prevotella melani-
nogena, were decreased after the use of prebiotics. These
studies have further demonstrated that the probiotics and
prebiotics may be beneficial to regulate oral microbiota
dysbiosis in HIV infection and prevent and reduce the
occurrence of HIV-related oral diseases. However, the oral
microbiome could be influenced by multiple factors. It is
necessary to identify specific bacteria that are beneficial
to preventing and treating HIV-related diseases. Further
clinical studies are also needed to determine the efficacy
and safety of probiotics in different clinical conditions.

Conclusion
Increasing evidence suggests a significant link of oral
microbiome changes to HIV infection. We summarized the
recent findings on alterations in oral microbiota of HIV
infection and the potential roles of the shifts in oral
microbiota in HIV-associated oral diseases. Moreover, we
reviewed the effects of ART and probiotics on oral
microbiota in HIV-infected individuals. It is evident that
the oral microbiome plays an essential role in the
pathogenesis of HIV disease, and a better understanding
of the oral microbiome might improve the oral health of
HIV-infected patients. In addition, further investigations
are needed to evaluate the impact of the potential
interventions on oral microbiome in HIV infection, which
is groundwork for the formidable task of developing novel
approaches for the prevention and therapy of HIV/AIDS-
associated diseases.

Funding
This work was supported by the National Natural Science
Foundation of China (Nos. 82072271, 81772165,
and 81974303), the National 13th Five-Year Grand
Program (No. 81761128001), and the Beijing Key
Laboratory for HIV/AIDS Research (No. BZ0089).

Conflicts of interest
None.

References
1. Patil S, Majumdar B, Sarode SC, Sarode GS, Awon KH.
Oral H. influenzae candidosis in HIV-infected patients-an update.
Front Microbiol 2018;9:980. doi: 10.3389/fmirc.2018.00980.
eCollection 2018.
2. Thompson GR 3rd, Patel PK, Kirkpatrick WR, Westbrook SD, Berg
D, Erlandsen J, D, et al. Oral H. influenzae candidosis in the era of
antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 2010;109:488–495. doi: 10.1016/j.tripleo.2009.11.026.
3. Polvora TLS, Nobre AVV, Tirapelli C, Taba M Jr, de Macedo LD,
Santana RC, et al. Relationship between human immunodeficiency
virus (HIV-1) infection and oral periodontitis. Expert Rev Clin
Immunol 2018;14:315–327. doi: 10.1080/1744666X.2018.1459571.
4. Noguera-Julian M, Guillen Y, Peterson J, Reznik D, Harris EV,
Joseph SJ, et al. Oral microbiome in HIV-associated periodontitis.
Medicine (Baltimore) 2017;96:e5821. doi: 10.1097/
MD.0000000000005821.
5. Rhoades N, Mendoza N, Jankeel A, Sureshchandra S, Alvarez AD,
Doratt B, et al. Altered immunity and microbial dysbiosis in aged
individuals with long-term controlled HIV infection. Front Immunol 2019;10:463. doi: 10.3389/fimmu.2019.00463. eCollection 2019.
6. Ziaziari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato
C, et al. Immune activation, inflammation, and non-AIDS co-
morbidities in HIV-infected patients under long-term ART. Viruses
2019;11:200. doi: 10.3390/v11030200.
7. Desai SN, Landay AL. HIV and aging: role of the microbiome.
Curr Opin HIV AIDS 2018;13:22–27. doi: 10.1097/
COH.0000000000000433.
8. Ryder M, Shiboski C, Yao TJ, Moscicki AB. Current trends and
new developments in HIV research and periodontal diseases.
Periodontol 2000 2020;82:65–77. doi: 10.1111/prd.12321.
9. Rocafort M, Noguera-Julian M, Rivera J, Pastor L, Guillen Y,
Langhorst J, et al. Evolution of the gut microbiome following acute
HIV-1 infection. Microbiome 2019;7:73. doi: 10.1186/s40168-
019-0687-5.
10. Armstrong AJ, Shaffer M, Nusbauser NM, Griesmer C, Fiorillo S,
Schnell J, et al. Microbiota associated with HIV infection in
men who have sex with men. Microbiome 2018;6:198. doi:
10.1186/s40168-018-0580-7.
11. Lozupone CA, Li M, Campbell TB, Flores SC, Linderman D,
Gebert MJ, et al. Alterations in the gut microbiota associated with
HIV-1 infection. Cell Host Microbe 2013;14:329–339. doi:
10.1016/j.chom.2013.08.006.
12. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK,
et al. An altered intestinal mucosal microbiome in HIV-1 infection
is associated with mucosal and systemic immune activation and
endotoxemia. Mucosal Immunol 2014;7:983–994. doi: 10.1038/
mic.2013.116.
13. Dillon SM, Lee EJ, Kotter CV, Austin GL, Gianella S, Siewe B, et al.
Gut dendritic cell activation links an altered colonic microbiome to
mucosal and systemic T-cell activation in untreated HIV-
1 infection. Mucosal Immunol 2016;9:24–37. doi: 10.1038/
mic.2015.33.
14. Koay WLA, Siens LV, Persaud D. The microbiome and HIV
persistence: implications for viral remission and cure.
Curr Opin HIV AIDS 2018;13:61–68. doi: 10.1097/COH.
0000000000000434.
15. Annavajhala MK, Khan SD, Sullivan SB, Shah J, Pass L, Kister K,
et al. Oral and gut microbial diversity and immune regulation in
patients with HIV on antiretroviral therapy. mSphere 2020;5:
e00798–e00819. doi: 10.1128/mSphere.00798-19.
16. Yang X, Su B, Zhang X, Liu Y, Wu H, Zhang T. Complete immune
reconstitution in HIV/AIDS patients on antiretroviral
therapy: challenges of immunological non-responders. J Leukoc
Biol 2020:107:597–612. doi: 10.1002/jlb.4MR1019-1899.
17. Brenchley JM, Price NA, Schacker TW, Asher TE, Silvastrini G,
Rao S, et al. Microbial translocation is a cause of systemic
immune activation in chronic HIV infection. Nat Med 2006;12:1365–
1371. doi: 10.1038/nm1511.
18. Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction,
microbial dysbiosis, and their role in HIV-1 disease progression.
J Infect Dis 2016;214:558–566. doi: 10.1093/infdis/jiw258.
19. Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm
K, et al. Gut microbiota diversity predicts immune status in HIV-
1 infection. AIDS 2015;29:2409–2418. doi: 10.1097/QAD.
0000000000000869.
20. Schuetz A, Delege C, Sereti I, Rerkmitir P, Phanuphak N,
Phuang-Ngern Y, et al. Initiation of ART during early acute HIV
infection preserves mucosal Th17 function and reverses HIV-
related immune activation. PLoS Pathog 2014;10:e1004543. doi: 10.1371/journal.ppat.1004543.
21. Hernandez-Santos N, Huppler AR, Peterson AC, Khader SA,
McKenna KC, Gaffen SL. Th17 cells confer long-term adaptive
immunity to oral mucosal Candida albicans infections. Mucosal
Immunol 2013;6:900–910. doi: 10.1038/mi.2012.128.
22. Kirchner PR, LeibundGut-Landmann S. Tissue-resident memory
Th17 cells maintain stable fungal commensalism in the oral
mucosa. Mucosal Immunol 2021;14:445–467. doi: 10.1038/
s41385-020-0327-0.
23. Conti HR, Peterson AC, Brane L, Huppler AR, Hernandez-
Santos N, Whiteley N, et al. Oral-resident natural Th17 cells and
gammadelta T cells control opportunistic Candida albicans
infections. J Exp Med 2014;211:2073–2084. doi: 10.1084/
jem.20130877.
infection. Microbiome 2018;6:100. doi: 10.1186/s41068-018-0464-6.

66. Hager CL, Ghannoun MA. The mycobiome in HIV. Curr Opin HIV AIDS 2018;13:69–72. doi: 10.1097/COH.0000000000000432.

67. Mukherjee PK, Chandra J, Retuerto M, Sikaroodi M, Brown RE, Jurevič R, et al. Oral microbiome analysis of HIV-infected patients: identification of Pichia as a predominant opportunistic fungus. PLoS Pathog 2014;10:e1003996. doi: 10.1371/journal.ppat.1003996. eCollection 2014 Mar.

68. Fidel PL Jr, Thompson Z, Lilly EA, Granada C, Treas K, Dubois KR 3rd, et al. Effect of HIV/HAAART and other clinical variables on the oral microbiome using multivariate analyses. mBio 2021;12:e00294–e00321. doi: 10.1128/mBio.00294-21.

69. Armstrong-Davies J, Stiers G, Brown GD. A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol 2014;22:120–127. doi: 10.1016/j.tim.2014.01.001.

70. Pour AH, Salari S, Almani PGN. Orfhyponagal candidiasis in HIV-positive pancreatic cancer patients in the southeast of Iran. Curr Med Mycol 2018;4:1–6. doi: 10.18502/cmm.v4i4.379.

71. Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell 2018;9:488–500. doi: 10.1007/s13238-018-0508-1.

72. Zhang HN, Zhou XD, Xu X, Wang Y. Oral microbiota and inflammatory bowel disease (in Chinese). West China journal of stomatology 2019;37:744–749. doi: 10.13877/j.issn.2009.04.020.

73. Said HS, Suda W, Nakagome S, Chinen H, Oshima K, Kim S, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral and gastrointestinal biomarkers. DNA Res 2014;21:13–25. doi: 10.1093/dnares/dst037.

74. Qi Y, Zhang Q, Wei J, Yu HC, Yang Z, Wu HM, et al. High-throughput sequencing provides insights into oral microbiota dysbiosis in association with inflammatory bowel disease. Genomics 2021;113:664–676. doi: 10.1016/j.ygeno.2020.09.063.

75. Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight 2017;2:e94416. doi: 10.1172/jci.insight.94416.

76. Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic disease in elderly patients. J Gastroenterol 2022;61:282–288. doi: 10.1038/s41377-021-01078-9.

77. Gaiser RA, Halimi A, Alakharan H, Lu L, Davadian H, Healy K, et al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut 2019;68:2184–2194. doi: 10.1136/gutjnl-2018-313791.

78. Wu YF, Lee WF, Salamanca E, Yao WL, Su JN, Wang SY, et al. Oral microbiota changes in elderly patients, an indicator of Alzheimer’s Disease. Int J Environ Res Public Health 2021;18:24211. doi: 10.3390/ijerph181082411.

79. Sureda A, Daglia M, Castilla SA, Sanadogol N, Nahavif SE, Khan H, et al. Oral microbiota and Alzheimer’s disease: do all roads lead to Rome? Pharmacol Res 2020;151:104582. doi: 10.1016/j.phrs.2019.104582.

80. Casarín RCV, Barbagallo A, Mealum T, Santos VR, Sallum EA, Nociti FH, et al. Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis. J Periodontol 2013;84:30–36. doi: 10.1111/j.1600-0765.2012.01498.x.

81. Tong Y, Zheng L, Qing P, Zhao H, Li Y, Su L, et al. Oral microbiota perturbations are linked to high risk for rheumatoid arthritis. Front Cell Infect Microbiol 2019;9:475. doi: 10.3389/fcimb.2019.00475. eCollection 2019.

82. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in the development of inflammatory arthritis and partly normalized after treatment. Nat Med 2015;21:895–905. doi: 10.1038/nm.3914.

83. Liu XR, Xu Q, Xiao J, Deng YM, Tang ZH, Tang YL, et al. Role of oral microbiota in atherosclerosis. Clin Chim Acta 2020;506:191–196. doi: 10.1016/j.cca.2020.03.033.

84. Madianos PN, Bobetis YA, Offenbacher S. Adverse pregnancy outcomes (APOs) and periodontal disease: pathogenic mechanisms. J Periodontol 2013;84:S170–S180. doi: 10.1902/jop.2013.1340015.

85. Li N, Li Y, Qian C, Liu Q, Cao W, Ma M, et al. Dysbiosis of the saliva microbiome in patients with polycystic ovary syndrome.
104. Jakubczyk D, Lesczynska K, Gorska S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD): A Critical Review. Nutrients 2020;12:1973. doi: 10.3390/nu12071973.

105. Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol 2020;145:16–27. doi: 10.1016/j.jaci.2019.11.003.

106. Goldenberg JZ, Yap C, Lytvyn L, Lo CKF, Beardsley J, Mertz D, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017;5:CD006095. doi:10.1002/14651858.CD006095.pub3.

107. West CE, Dzidic M, Prescott SL, Jenmalm MC. Bugging allergy; role of pre-, pro- and synbiotics in allergy prevention. Allergol Int 2017;66:529–538. doi: 10.1016/j.alit.2017.08.001.

108. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med 2019;25:716–729. doi:10.1038/s41591-019-0439-x.

109. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2015;2:CD006895. doi: 10.1002/14651858.

110. Hu J, Zhang L, Lin W, Tang W, Chan FKL, Ng SC. Review article: probiotics, prebiotics and dietary approaches during COVID-19 pandemic. Trends Food Sci Technol 2021;108:187–196. doi: 10.1016/j.tifs.2020.12.009.

111. Bustamante M, Oomah BD, Mosi-Roa Y, Rubilar M, Burgos-Diaz C. Probiotics as an adjunct therapy for the treatment of halitosis, dental caries and periodontitis. Probiotics Antimicrob Proteins 2020;12:325–334. doi: 10.1007/s12602-019-00521-4.

112. Montero E, Iniesta M, Rodrigo M, Marin MJ, Figuero E, Herrera D, et al. Clinical and microbiological effects of the adjunctive use of probiotics in the treatment of gingivitis: a randomized controlled clinical trial. J Clin Periodontol 2017;44:708–716. doi: 10.1111/jcpe.12752.

113. Invernici MM, Salvador SL, Silva PHF, Soares MSM, Casarin R, Paloto DB, et al. Effects of bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial. J Clin Periodontol 2018;45:1198–1210. doi: 10.1111/jcpe.12495.

114. Mundula T, Ricci F, Barbeta B, Baccini M, Amedei A. Effect of probiotics on oral candidiasis: a systematic review and meta-analysis. Nutrients 2019;11:2449. doi: 10.3390/nu11102449.

115. Chanda W, Joseph TP, Wang W, Padhiar AA, Zhong M. The potential management of oral candidiasis using anti-biofilm therapies. Med Hypotheses 2017;106:15–18. doi: 10.1016/j.mehy.2017.06.029.

116. de Barros PP, Scorzoni L, de Camargo Ribeiro F, de Oliveira Fugisaki LR, Fuchs BB, Mylonakis E, et al. Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans. Microb Pathog. 2018;117:80–87. doi: 10.1016/j.micpath.2018.02.019.

117. Leao MVP, Tavares TAA, Goncalves ECR, Dos Santos SSF, Junqueira JC, de Oliveira LD, et al. Lactobacillus rhamnosus intake can prevent the development of Candidiasis. Clin Oral Invest 2018;22:2511–2518. doi: 10.1007/s00784-018-2347-8.

118. Salari S, Almani PGN. Antifungal effects of Lactobacillus acidophilus and Lactobacillus plantarum against different oral Candida species isolated from HIV/AIDS patients: an in vitro study. J Oral Microbiol 2020;12:1769386. doi: 10.1080/20002297.2020.1769386.

119. Slomka V, Hernandez-Sanabria E, Herrero ER, Zaidel L, Bernaerts K, Boon N, et al. Nutritional stimulation of commensal oral bacteria suppresses pathogens: the prebiotic concept. J Clin Periodontol 2017;44:344–352. doi: 10.1111/jcpe.12700.

120. Slomka V, Herrero ER, Boon N, Bernaerts K, Trivedi HM, Daep C, et al. Oral prebiotics and the influence of environmental conditions in vitro. J Periodontol 2018;89:708–717. doi: 10.1002/jper.17-0437.